LDS/Medical Tests/Factor IX Gene Gene Mutation Analysis

Factor IX Gene Gene Mutation Analysis

Factor IX (FIX), a vitamin K dependent plasma protein manufactured by the liver, plays a central role in both the intrinsic phase and extrinsic pathways of blood coagulation. Hemophilia B is an X-linked recessive blood coagulation disorder resulting from mutations of the factor 9 gene, located on the long arm of the X chromosome at Xq27.1. Mutations have been reported in all regions of the FIX gene, including: exon encoding protein domains, regulatory regions, and the poly A tail. The functional FIX protein contains the G1a region, a result of gamma-carboxylation, which is characteristic of all Vitamin K dependent enzymes. The G1a region is responsible for binding with calcium, which allows binding with phospholipid membrane so that FIX can develop its complete activity. Warfarin interferes with this carboxylation with resultant absent or markedly reduced activity of Vitamin K dependent enzymes. With 100% penetrance in males and a 10% penetrance in females, approximately 1 in 25,000 males are affected by hemophilia B. Hemophilia B accounts for 12% of total hemophilia cases, and its clinical manifestations may be indistinguishable from hemophilia A. Disease severity is usually correlative with circulating plasma FIX levels. Hemophilia B is classified as mild, moderate, or severe. Mild: 5-30% circulating factor IX levels. Absence of spontaneous bleeding episodes. Abnormal bleeding occurs after surgery / tooth extraction and requires corrective pre-op and post-op treatment. Usually diagnosed later in life. Moderate: 1-5% circulating factor IX levels. Occasional spontaneous bleeding episodes. Prolonged or delayed oozing after minor trauma. Usually diagnosed before age 6. Severe: < 1% circulating factor IX levels. Spontaneous joint or deep muscle bleeding. Usually diagnosed during the first year of life.
  • Carrier testing for females with unknown familial F9 genotype.
  • Diagnostic testing for individuals with a family history of hemophilia.
  • Testing in patients with symptoms suggestive of a coagulation disorder such as spontaneous or prolonged bleeding.
  • Testing of individuals with acute onset of bleeding in the presence of prolonged partial thromboplastin time (PTT).
  • Prenatal / preimplantation genetic diagnosis (PGD) for at-risk pregnancies.
  • Identification of specific mutation. Beneficial in the determination of probable disease severity, risk assessment for inhibitor development, and risk assessment of anaphylaxis due to inhibitor development.
  • Positive: a mutation has been detected in the factor IX gene. Interpretive report will be issued containing information regarding specific mutation and carrier status.
  • Negative: no mutations were detected in the factor IX gene.
  • Negative results are not exclusionary for hemophilia B. Deep gene mutations and intronic mutations will not be detected in either male or female patients. Large deletions will not be detected in females.

Negative for mutation analyzed (Mutation Not Detected)

Affinity chromatography, ion-exchange chromatography, polymerase chain reaction (PCR), sequence analysis, deletion / duplication analysis, linkage analysis

Whole blood EDTA (lavender top tube) or ACD (blue top tube).

SStability

    • Ambient: 3-5 days
    • Refrigerated: 5-7 days
    • Frozen: 30 days
Complete blood count (CBC) including platelet count, platelet function analysis (PFA), prothrombin time, partial thromboplastin time, factor VIII level, factor IX level, von wilebrand factor (VWF) level, fibrinogen, genetic counseling.
5-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Thromb Haemost. 2013 Aug;11(8):1449-53. [PMID: 23763284]
  • N Engl J Med. 2009 Oct 22;361(17): 1671-1675. [PMID: 19846852]
  • Konkle BA, Josephson NC, Nakaya Fletcher SM, Thompson AR. NCBI bookshelf. Hemophilia B. Seattle: University of Washington, 2011.
  • Roth D, Freedman S, Furie B. "Biochemistry of Factor IX and Molecular Biology of Hemophilia B." Hematology Basic Principles and Practice, 5th edition. Hoffman R et al., (eds). Philadelphia: Churchill Livingstone Elsevier, 2009. 1899-1908.